Adherent cells from placenta tissue and use thereof in therapy
A method of culturing adherent cells from a placenta or adipose tissue is disclosed. The method comprising culturing the adherent cells from the placenta or adipose tissue under 2 dimensional (2D) culturing conditions which allow cell expansion, the conditions comprising continuous passaging of the cells for at least 4 passages.
1. A method of culturing undifferentiated adherent cells from a human placenta, the method comprising:
(i) culturing the undifferentiated adherent cells from the human placenta under 2 dimensional (2D) culturing conditions which allow differentiation-less cell expansion, said conditions comprising passaging of said cells for at least 4 passages and growing the cells in a culture medium devoid of an antibiotic from at least passage 2, wherein the undifferentiated adherent cells have been obtained by enzymatic digestion of said placenta, are heterogeneous with regards to fetal versus maternal origin and are negative for CD11b, CD34, HLA-DR, CD14, CD19, CD200 and CD45; and,
(ii) after culturing, freezing the undifferentiated adherent cells in a controlled temperature reducing process, comprising lowering the temperature at a rate of a predetermined number of degrees per minute.
2. The method of claim 1 , further comprising obtaining the undifferentiated adherent cells from the human placenta by enzymatically digesting human placental tissue to release said cells, and allowing the released cells to adhere to a culture surface.
3. The method of claim 2 , wherein the human placental tissue is enzymatically digested with collagenase.
4. The method of claim 1 , wherein the step of freezing the undifferentiated adherent cells is performed at a passage in a range of 6 to 9 passages.
5. The method of claim 1 , wherein the step of freezing the undifferentiated adherent cells is performed at a passage in a range of 5 to 8 passages.
6. The method of claim 5 , wherein the step of freezing the undifferentiated adherent cells is performed at a passage in a range of 5 to 6 passages.
7. The method of claim 1 , wherein the first passage is performed when the cells reach 7 to 15 days in culture.
8. The method of claim 1 , wherein, beginning at passage 2, and continuing for 6 to 8 passages, cells are passaged when the culture is at 70% to 90% confluence.
9. The method of claim 1 , wherein at each passage the cells are seeded at a density of 4±0.5×10 3 cells/cm 2 of culture surface.
10. The method of claim 1 , wherein the step of freezing comprises freezing the undifferentiated adherent cells at a concentration of about 10×10 6 cells/ml.
11. The method of claim 1 , wherein the adherent cells do not differentiate into osteocytes.
12. The method of claim 1 , wherein said adherent stromal cells are positive for a marker selected from the group consisting of CD73, CD90, CD29 and CD105.
13. The method of claim 12 , wherein said adherent cells are positive for CD73, CD90, CD29 and CD105.
14. The method of claim 1 further comprising expanding the undifferentiated adherent cells from the human placenta under three-dimensional (3D) culture conditions.
15. The method of claim 14 , wherein the 3D culture conditions comprise culturing of the undifferentiated adherent cells on 3D carriers in a bioreactor.